Experimental Drug for RRMS, SPMS Enters Phase 2 Trial

Lexington, MA-based biopharmaceutical company Xenetic Biosciences, Inc. has just announced its new license partner Pharmsynthezhas completed dosing in its ongoing Phase 2 clinical trial with pipeline product MyeloXen™for relapsing remitting and secondary progressive (SPMS) multiple sclerosis.

The MyeloXen trial is currently underway in Russia with 26 patients divided into 3 groups. The first group includes 6 healthy participants who received a single dose of the drug and were reported last year to have tolerated it well. The results from this cohort prompted dosing in two more groups. The 2nd and 3rd groups enrolled patients with relapsing remitting or secondary progressive MS with a determined Expanded Disability Status Scale (EDSS) of ≥3.0 and ≤5.5, who had experienced at least one exacerbation in the past year, and who had an unsuccessful treatment response to prior immunomodulation and/or immunosuppression therapy.

The patients received 6 increasing doses every week, beginning with 50μg up to 900μg. 15 patients completed the study and the follow up period, and exhibited good tolerance of multiple doses of MyeloXen up to 900μg. Additional follow up data is expected to be ready within Q1 2015.

Continue reading

~~~~~~~~~~~~~~~~~~~~

 Keep CURRENT with MS Views and News – OPT-IN here

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews